Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07219589
PHASE1

A Single Ascending Dose Study of HM17321 in Healthy Adult Participants

Sponsor: Hanmi Pharmaceutical Company Limited

View on ClinicalTrials.gov

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single ascending doses in healthy adult participants.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-11-06

Completion Date

2026-04

Last Updated

2026-02-25

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HM17321

Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.

DRUG

Placebo of HM17321

Participants will receive a single subcutaneous injection of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.

Locations (1)

Medpace Clinical Pharmacology Unit

Cincinnati, Ohio, United States